An observational study in Irritable Bowel Syndrome, Crohn Disease and Celiac Disease, sponsored by Nimble Science Ltd.. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Nimble Science Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Irritable Bowel Syndrome with a site in Canada — 8 open to participants now, 11 under way, 1 of them phase 3. Irritable Bowel Syndrome · Canada.
Among the 56 studies in Irritable Bowel Syndrome with a site in Canada, this one is one of 2 that started in 2023, is one of 4 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 44th registered.
1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.
Browse Irritable Bowel Syndrome studies →8 of the 56 studies in Irritable Bowel Syndrome with a site in Canada are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Canada, United States, Belgium and 7 more countries
Ages 18–75
Eli Lilly and Company · Sites in Canada, United States, Belgium and 5 more countries
Ages 18–75
David Reed · Sites in Canada
Ages 18–70
Hospital Universitari Vall d'Hebron Research Institute · Sites in Canada, United States, France and 4 more countries
Ages 18–80 · Healthy volunteers
McMaster University · Sites in Canada
Ages 18–70
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 10 · Phase 4 1
First in 1996; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 161 across 192 observational studies indexed under Irritable Bowel Syndrome.
Median enrollment 103 across the 52 interventional studies, 2,431 across the 4 observational. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 56 have an industry lead sponsor. The 10 most frequent:
Nimble Science Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Nimble Science Ltd. has 2 studies filed under Irritable Bowel Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Irritable Bowel Syndrome with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06317441Nimble Science Ltd.The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms | 2027-04 |
| NCT06369753Hospital Universitari Vall d'Hebron Research InstituteVisible Abdominal Distension | 2027-04 |
| NCT05633706Nimble Science Ltd.Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis | 2027-06 |
| NCT07545772Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | 2027-07 |
| NCT07545759Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Irritable Bowel Syndrome with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means. The study will compare the microbial and metabolomics analysis from the sample collected with the capsule series, to same-participant symptom questionnaires and stool microbial analysis.
The investigators primary goal is to assess the correlation of gut symptoms from various disease states with the dysbiosis of the small intestinal microbiome and metabolites collected by the SIMBA capsule, and as identified and measured by metagenomic sequencing and/or metabolomics approaches. The process consists of ingestion and collection of up to 4 SIMBA capsules, on up to 2 separate occasions, along with collection of a stool sample at the same time. Participants will also fill out a series of questionnaires on medical history and lifestyle inputs (eg. diet, exercise, mental health) GI symptoms, anxiety, and depression. The investigators ultimate goal will be to develop a better understanding of how the small intestinal microbiome might play a role in symptom generation, to establish whether the SIMBA capsule can find a signature of dysbiosis which can be used as a biomarker for a number of functional gut disorders.
Up to 300 individuals, females or males will be enrolled in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Use of any medications or having undergone procedures in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, laxatives, or GLP-1 analogues).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Not belonging to the other cohorts as described below.
Device: fluid biopsy capsule
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Device: fluid biopsy capsule
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Device: fluid biopsy capsule
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Device: fluid biopsy capsule
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Device: fluid biopsy capsule
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Device: fluid biopsy capsule
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Device: fluid biopsy capsule
Collection of a fluid biopsy from the small intestine via ingestible capsule
Correlation of bacterial composition with gastrointestinal disease states as assessed by PLS-DA mapping.
The bacterial composition of healthy control fluid biopsy is compared to the bacterial composition of participants with diagnosed gastrointestinal diseases, to aid in gastrointestinal disease biomarker discovery.
Time frame: baseline, pre-procedure
Correlation of bacterial composition with dietary intake as assessed by PLS-DA mapping.
Fluid biopsy bacterial composition correlated with self-reported long-term and short-term preferred variations in intake of dietary fiber and organic food.
Time frame: baseline, pre-procedure
Usability of SIMBA capsule in various disease states as assessed by SIMBA-experience questionnaires.
Participant feedback on SIMBA capsule usage experience will inform usability data.
Time frame: immediately after the procedure
Comparison of SIMBA fluid biopsy microbial composition to stool microbial composition as assessed by 16s rRNA metagenomic analysis.
Time frame: baseline, pre-procedure
Correlations of bacterial composition with anxiety (GAD-7) scores as assessed by PCoA mapping, alpha and beta diversity analysis.
Time frame: baseline, pre-procedure
Correlations of bacterial composition with depression (PHQ-8) scores as assessed by PCoA mapping, alpha and beta diversity analysis.
Time frame: baseline, pre-procedure
Correlations of bacterial composition with self-reported lifestyle behaviours as assessed by PCoA mapping, alpha and beta diversity analysis.
Time frame: baseline, pre-procedure
Number of participants with device-related adverse events as assessed by an independent Data Safety Monitoring Board.
Time frame: through study completion, an average of 8 days
Evaluate the usability of excreted SIMBA Capsule retrieval procedures as assessed by retrieval-experience questionnaire feedback.
Time frame: immediately after the procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Jun 2027, 53 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jun 2025 → Jun 2027 and completion Jun 2025 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nimble Science Ltd.